Innoviva (INVA) Amortization of Deferred Charges (2013 - 2026)
Innoviva (INVA) posted Amortization of Deferred Charges of $364000.0 for Q1 2026, down 76.26% on a QoQ basis from $1.5 million in Q3 2025, and down 32.72% year-over-year from $541000.0 in Q1 2025.
Innoviva (INVA) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends
Innoviva's Amortization of Deferred Charges history runs 14 years deep, the most recent figure standing at $364000.0 for Q1 2026.
- Quarterly Amortization of Deferred Charges fell 32.72% year-over-year to $364000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.0 million (down 6.15% YoY) and the FY2025 annual result came in at $1.9 million, down 10.57% from the prior year.
- Amortization of Deferred Charges was $364000.0 for Q1 2026 at Innoviva, down from $1.5 million in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $1.6 million in Q3 2024 and bottomed at $364000.0 in Q1 2026.
- A 5-year average of $815923.1 and a median of $537000.0 in 2025 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges sank 82.95% — and 2023, when it surged 38.73%.
- Innoviva's Amortization of Deferred Charges stood at $1.5 million in 2022, then gained by 3.89% to $1.5 million in 2023, then rose by 2.07% to $1.6 million in 2024, then slipped by 3.04% to $1.5 million in 2025, then sank by 76.26% to $364000.0 in 2026.
- Business Quant data shows INVA's Amortization of Deferred Charges at $364000.0 in Q1 2026, $1.5 million in Q3 2025, and $537000.0 in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,071.81 Bn | - |
| 2 | Nanobiotix | 1,925.70 Bn | 1,925.64 Bn | - |
| 3 | Akari Therapeutics | 1,062.88 Bn | 1,062.88 Bn | - |
| 4 | BeOne Medicines | 469.09 Bn | 464.29 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.09 Bn | 115.84 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.32 Bn | 61.57 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.36 Bn | 63.36 Bn | - |
| 8 | Argenx Se | 55.90 Bn | 50.71 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.69 Bn | 34.68 Bn | 959.66 Mn |
| 10 | Innoviva | 1.61 Bn | 1.01 Bn | 75.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 364,000.00 |
| Mar 31, 2026 | 364,000.00 |
| Sep 30, 2025 | 1.53 Mn |
| Sep 30, 2025 | 1.53 Mn |
| Jun 30, 2025 | 537,000.00 |
| Jun 30, 2025 | 537,000.00 |
| Mar 31, 2025 | 541,000.00 |
| Mar 31, 2025 | 541,000.00 |
| Sep 30, 2024 | 1.58 Mn |
| Sep 30, 2024 | 1.58 Mn |
| Jun 30, 2024 | 523,000.00 |
| Jun 30, 2024 | 523,000.00 |
| Mar 31, 2024 | 525,000.00 |
| Mar 31, 2024 | 525,000.00 |
| Sep 30, 2023 | 1.55 Mn |
| Sep 30, 2023 | 1.55 Mn |
| Jun 30, 2023 | 509,000.00 |
| Jun 30, 2023 | 509,000.00 |
| Mar 31, 2023 | 523,000.00 |
| Mar 31, 2023 | 523,000.00 |